AXGN Axogen, Inc. - Common Stock

NAS · US · Healthcare · Medical Devices · axogeninc.com

37.39USD-6.34%Mkt Cap: 2.19B $P/E: —3d ago

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a pro…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.60BUSDP/E 18.7

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

Key Statistics

Company

Market Cap2.19B USD

Enterprise Value2.05B USD

Revenue (TTM)251.17M USD

Gross Profit167.35M USD

Net Income (TTM)-15.70M USD

Revenue/Share5.07 USD

Last Price37.39 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees622

CountryUS

SectorHealthcare

IndustryMedical Devices

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)57.86

PEG99.04

EV/EBITDA-344.31

EV/Revenue8.18

P/S9.32

P/B8.36

EPS (TTM)-0.68

EPS (Forward)0.69

52W Range

15.2760% of range52.43

52W High52.43 USD

52W Low15.27 USD

Profitability

Gross Margin74.31%

Oper. Margin-3.09%

EBITDA Margin-2.38%

Profit Margin-6.97%

ROE-12.19%

ROA-7.08%

Growth

Revenue Growth23.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF812.00K USD

CapEx (TTM)5.59M USD

FCF Margin7.26%

FCF Yield0.83%

Net Debt-91.35M USD

Net Debt/EBITDA15.31

Balance Sheet

Debt/Equity0.52

Current Ratio6.60

Quick Ratio4.79

Book Value/Sh4.78 USD

Cash/Share2.07 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateJan 27, 2010

Pay DateFeb 12, 2010

Splits

Last Split105:100

Split DateJul 11, 1994

Analyst Consensus

Rating1.2 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)53.70 USD

Upside (mean)+43.6%

Target Range48.00 USD – 58.00 USD

48.00+43.6% to mean58.00

# Analysts10

Ownership

Shares Out.58.67M

Float52.72M

Insiders1.98%

Institutions91.39%

Short Interest

Short Ratio3.5d

Short % Float7.89%

Short % Out.6.91%

Shares Short4.06M

Short (prev mo.)3.37M

Technical

SMA 5045.80 (-18.4%)

SMA 20038.86 (-3.8%)

Beta1.16

S&P 52W Chg13.94%

Avg Vol (30d)1.22M

Avg Vol (10d)1.11M

Technical Indicators

RSI (14)28.8

MACD-1.5752

MACD Signal-0.8537

MACD Hist.-0.7215

BB Upper49.56 USD

BB Middle44.01 USD

BB Lower38.46 USD

BB Width25.21%

ATR (14)2.263 USD

Vol Ratio (20d)2.37x